CN102202690A - 作为人上皮细胞免疫刺激活性增强剂的抑瘤素m - Google Patents

作为人上皮细胞免疫刺激活性增强剂的抑瘤素m Download PDF

Info

Publication number
CN102202690A
CN102202690A CN2009801443381A CN200980144338A CN102202690A CN 102202690 A CN102202690 A CN 102202690A CN 2009801443381 A CN2009801443381 A CN 2009801443381A CN 200980144338 A CN200980144338 A CN 200980144338A CN 102202690 A CN102202690 A CN 102202690A
Authority
CN
China
Prior art keywords
osm
cells
cell
ifn
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801443381A
Other languages
English (en)
Chinese (zh)
Inventor
拉斐尔·阿尔达比阿里奎
伊兰祖·宫扎莱兹德拉塔贾德
玛利亚·埃丝特·拉瑞莱欧兹
赫苏斯·玛利亚·普列托巴尔图埃纳
帕布鲁·萨罗韦乌加里萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of CN102202690A publication Critical patent/CN102202690A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2009801443381A 2008-10-07 2009-10-06 作为人上皮细胞免疫刺激活性增强剂的抑瘤素m Pending CN102202690A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200802835 2008-10-07
ES200802835A ES2342529B1 (es) 2008-10-07 2008-10-07 Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
PCT/ES2009/070419 WO2010040882A1 (es) 2008-10-07 2009-10-06 Oncostatina m como potenciador de la actividad inmunoestimuladora de células epiteliales humanas

Publications (1)

Publication Number Publication Date
CN102202690A true CN102202690A (zh) 2011-09-28

Family

ID=41478601

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801443381A Pending CN102202690A (zh) 2008-10-07 2009-10-06 作为人上皮细胞免疫刺激活性增强剂的抑瘤素m

Country Status (11)

Country Link
US (1) US20110195047A1 (https=)
EP (1) EP2345423A1 (https=)
JP (1) JP2012504948A (https=)
CN (1) CN102202690A (https=)
AU (1) AU2009301067A1 (https=)
BR (1) BRPI0920662A2 (https=)
CA (1) CA2739670A1 (https=)
ES (1) ES2342529B1 (https=)
MX (1) MX2011003676A (https=)
RU (1) RU2011118362A (https=)
WO (1) WO2010040882A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104096219A (zh) * 2014-07-08 2014-10-15 武汉大学 Ⅱ型抑瘤素m受体（osmr）在治疗脂肪肝和ⅱ型糖尿病中的功能和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102352368B (zh) * 2011-09-29 2013-12-04 苏州大学 Ing4与osm双基因共表达载体及其应用
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
CN105829893A (zh) * 2013-06-14 2016-08-03 西班牙格拉纳达大学 用于胰腺癌诊断及治疗响应的生物标记物
WO2015089380A2 (en) * 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
WO2018175251A1 (en) 2017-03-20 2018-09-27 Celcuity Llc Methods of measuring signaling pathway activity for selection of therapeutic agents
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1346279A (zh) * 1999-02-12 2002-04-24 斯克里普斯研究学院 联合应用抗血管生成和免疫治疗以治疗肿瘤和转移的方法
US20020119121A1 (en) * 2000-09-15 2002-08-29 Vitiello Maria Antonella Compositions and methods for inducing specific cytolytic T cell responses
WO2004053113A1 (en) * 2002-12-09 2004-06-24 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland In vitro immunization
CN101001615A (zh) * 2004-06-16 2007-07-18 加里·R·奥斯特罗夫 药物输送产品和方法
EP1905447A2 (en) * 2005-06-16 2008-04-02 Proyecto de Biomedicina Cima, S.L. Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha
CN101203247A (zh) * 2005-01-10 2008-06-18 研究发展基金会 用于癌症治疗的靶向嵌合分子

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
IL112768A (en) 1989-04-10 1998-06-15 Oncogen Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
JP2004026768A (ja) 2002-06-27 2004-01-29 Kanagawa Acad Of Sci & Technol 肝疾患治療又は予防薬
US7572896B2 (en) 2005-02-03 2009-08-11 Raven Biotechnologies, Inc. Antibodies to oncostatin M receptor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1346279A (zh) * 1999-02-12 2002-04-24 斯克里普斯研究学院 联合应用抗血管生成和免疫治疗以治疗肿瘤和转移的方法
US20020119121A1 (en) * 2000-09-15 2002-08-29 Vitiello Maria Antonella Compositions and methods for inducing specific cytolytic T cell responses
WO2004053113A1 (en) * 2002-12-09 2004-06-24 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland In vitro immunization
CN101001615A (zh) * 2004-06-16 2007-07-18 加里·R·奥斯特罗夫 药物输送产品和方法
CN101203247A (zh) * 2005-01-10 2008-06-18 研究发展基金会 用于癌症治疗的靶向嵌合分子
EP1905447A2 (en) * 2005-06-16 2008-04-02 Proyecto de Biomedicina Cima, S.L. Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha
CN101257918A (zh) * 2005-06-16 2008-09-03 西马生物医学计划公司 来自白介素-6家族的细胞因子在用于与干扰素-α组合施用的组合物的制备中的用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ESTHER LARREA ET AL: "Oncostatin M Enhances the Antiviral Effects of Type I Interferon and Activates Immunostimulatory Functions in Liver Epithelial Cells", 《JOURNAL OF VIROLOGY》 *
刘京生等: "细胞因子诱导肿瘤细胞凋亡的实验研究", 《河北医药》 *
刘树铮主编: "《医学放射生物学》", 31 December 1998, 北京市：原子能出版社 *
孙强玲: "HBV启动子调控的肝细胞高表达载体构建及抑癌作用研究", 《军事医学科学院放射医学研究所硕士学位论文》 *
方杰主编: "《辐射防护理论》", 30 June 1991, 北京市：原子能出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104096219A (zh) * 2014-07-08 2014-10-15 武汉大学 Ⅱ型抑瘤素m受体（osmr）在治疗脂肪肝和ⅱ型糖尿病中的功能和应用

Also Published As

Publication number Publication date
ES2342529A1 (es) 2010-07-07
JP2012504948A (ja) 2012-03-01
RU2011118362A (ru) 2012-11-20
CA2739670A1 (en) 2010-04-15
MX2011003676A (es) 2011-05-02
AU2009301067A1 (en) 2010-04-15
US20110195047A1 (en) 2011-08-11
BRPI0920662A2 (pt) 2018-06-26
EP2345423A1 (en) 2011-07-20
WO2010040882A1 (es) 2010-04-15
ES2342529B1 (es) 2011-05-11

Similar Documents

Publication Publication Date Title
Tovey et al. Adjuvant activity of cytokines
CN1805758B (zh) 核酸和细胞疫苗的组分
Hoebe et al. LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif, Tram, and other TIR adaptor proteins
CN102202690A (zh) 作为人上皮细胞免疫刺激活性增强剂的抑瘤素m
US20090004142A1 (en) A cell therapy method for the treatment of tumors
CN101842113A (zh) 免疫诱导剂
JP2002509892A (ja) Ｈｓｐ７０タンパク質の新規使用
Inoue et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model
JP7181676B2 (ja) 免疫誘導剤
JP2001089389A (ja) 抗原特異的ｔ細胞の誘導剤
US20100129390A1 (en) Dkk1 as a universal tumor vaccine for immunotherapy of cancers
EP1074267B1 (en) Induction of antigen-specific T cells by interferon
KR101944723B1 (ko) I형 인터페론을 이용한 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
Xue et al. Dendritic cells modified with 6Ckine/IFNγ fusion gene induce specific cytotoxic T lymphocytes in vitro
EP2992898A1 (en) T-cell adjuvant and its use for therapeutic or prophylactic vaccination
JP7147168B2 (ja) 免疫誘導剤
CA2993427C (en) Immune inducer
WO2025096694A1 (en) Endogenous tgf-beta inhibited dendritic cells
Balman Investigation of type-I interferon regulated gene expression in murine dendritic cells
Sistigu Inflammatory and immune reactions in response to chemotherapy-induced cell death
Dezfouli et al. Research Article Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNγ primed and IFNβ treated B7-1+ B16-F10 melanoma cells.
JP2001026545A (ja) 免疫応答活性化製剤
NZ623917A (en) Antigen presenting cancer vaccine
HK1068805A (en) Cell therapy method for the treatment of tumours
WO2004069272A2 (en) Adjuvant combination for use in the immunization of a mamal comprising il2 and il12

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110928